Apexigen

Apexigen

A biopharmaceutical company developing antibodies for cancer, inflammatory diseases and ophthalmic diseases

No article has been written about this topic yet.
Paste a URL about this topic to auto-extract knowledge.
Visit our Writing Guide for help on how to write about a topic,
and check out an example of a well filled out topic page.

No article has been written about this topic yet.
Be the first one to add some text.

Loading AI-assisted edit mode...

Timeline

August 2018
Apexigen raises a $73,000,000 series B round from SV Tech Ventures, Decheng Capital, 3E Bioventures Capital and VI Ventures.
August 6, 2013
Apexigen raises a $20,000,000 series A round from Amkey Ventures and Sycamore Ventures.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Apexigen Inc funding round, August 2018
73,000,000
August 2018
123,000,000
March 24, 2020
4 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Apexigen, Inc.
January 8, 2021
www.prnewswire.com:443
/PRNewswire/ -- Apexigen, Inc., a clinical-stage biopharmaceutical company, today announced that Xiaodong Yang, M.D., Ph.D., President and Chief Executive...
BioSpace
November 9, 2020
BioSpace
Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, announced two upcoming poster presentations at the 35th Society for Immunotherapy of Cancer Annual Meeting, to be held November 9-14, 2020.
Apexigen, Inc.
November 9, 2020
www.prnewswire.com:443
/PRNewswire/ -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for...
BioSpace
June 4, 2020
BioSpace
Apexigen, Inc. announced the appointment of Gordon Ringold, Ph.D., to its Board of Directors.
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.